Abstract
Objective: To establish whether there has been any rise in the prevalence of non-albicans Candida species isolated from vaginal swabs since the introduction of "over the counter" antifungal treatments.
Method: A retrospective review looking at all positive vaginal yeast isolates collected from women attending one genitourinary medicine clinic during the 6 year period from 1993 to 1998 inclusive. All positive vaginal yeast isolates were included, regardless of whether or not the patients were symptomatic. Isolates from HIV positive women were excluded from the analysis.
Result: No increase in non-albicans vaginal yeast isolates was shown during the period studied. The proportion of non-albicans yeasts remained constant at approximately 5% of the total yeasts isolated. The most common non-albicans yeast isolated was C glabrata.
Conclusion: There is no evidence from this study to suggest that the increasing use of "over the counter" antifungal treatment has selected for atypical, possibly inherently azole resistant, strains of vaginal yeasts in HIV seronegative women.
Key Words: vulvovaginal candidiasis; non-albicans species; antifungal drug resistance
Full Text
The Full Text of this article is available as a PDF (61.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Denning D. W., Baily G. G., Hood S. V. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis. 1997 Apr;16(4):261–280. doi: 10.1007/BF01695630. [DOI] [PubMed] [Google Scholar]
- Ferris D. G., Dekle C., Litaker M. S. Women's use of over-the-counter antifungal medications for gynecologic symptoms. J Fam Pract. 1996 Jun;42(6):595–600. [PubMed] [Google Scholar]
- Lynch M. E., Sobel J. D. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol. 1994;32(4):267–274. [PubMed] [Google Scholar]
- Lynch M. E., Sobel J. D., Fidel P. L., Jr Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol. 1996 Sep-Oct;34(5):337–339. doi: 10.1080/02681219680000571. [DOI] [PubMed] [Google Scholar]
- Maenza J. R., Keruly J. C., Moore R. D., Chaisson R. E., Merz W. G., Gallant J. E. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996 Jan;173(1):219–225. doi: 10.1093/infdis/173.1.219. [DOI] [PubMed] [Google Scholar]
- Price M. F., LaRocco M. T., Gentry L. O. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994 Jun;38(6):1422–1424. doi: 10.1128/aac.38.6.1422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sobel J. D. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):924–935. doi: 10.1016/s0002-9378(85)80003-x. [DOI] [PubMed] [Google Scholar]
- Sobel J. D. Vaginal infections in adult women. Med Clin North Am. 1990 Nov;74(6):1573–1602. doi: 10.1016/s0025-7125(16)30496-5. [DOI] [PubMed] [Google Scholar]
- Sobel J. D., Vazquez J. A. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis. 1996 Apr;22(4):726–727. doi: 10.1093/clinids/22.4.726. [DOI] [PubMed] [Google Scholar]
- Spinillo A., Capuzzo E., Gulminetti R., Marone P., Colonna L., Piazzi G. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):138–141. doi: 10.1016/s0002-9378(97)80026-9. [DOI] [PubMed] [Google Scholar]